key: cord-0711275-zmsrkoxj
authors: Gattinger, Pia; Tulaeva, Inna; Borochova, Kristina; Kratzer, Bernhard; Trapin, Doris; Kropfmüller, Anna; Pickl, Winfried F.; Valenta, Rudolf
title: Omicron: A SARS‐CoV‐2 variant of real concern
date: 2022-02-28
journal: Allergy
DOI: 10.1111/all.15264
sha: c72cacece171dd9c0ff10163f93f611ec36951c4
doc_id: 711275
cord_uid: zmsrkoxj

nan

Additional supporting information may be found in the online version of the article at the publisher's website. DOI: 10 .1111/all.15264

To the Editor, As of today (February 14, 2022), more than 410 million persons were more than double as high as in the end of 2020, the number of COVID-19-associated deaths has dropped to approximately 50% at the same time (https://coron avirus.jhu.edu/map.html). However, the immunity to SARS-CoV-2 which has been established so far is challenged by the appearance of SARS-CoV-2-variants which may escape cellular (Supplemental reference S4) and antibody-dependent immunity (Supplemental reference S5). The recently described variant of concern (VOC) Omicron, which has emerged in South Africa in November 2021, is spreading in the meantime rapidly all over the world and has become a matter of great concern because it shows more changes in the SARS-CoV-2 genome that may affect immunity as compared with earlier variants 1 (Supplemental references S6-S9).

In particular, Omicron has significantly more amino acid mutations in the SARS-CoV-2 receptor-binding domain (RBD), which binds to the ACE2 receptor on human cells, as compared with previous SARS-CoV-2 variants 2 (Table S1 ). Antibodies directed to RBD are critically important for virus-neutralization because the RBD-ACE2 interaction represents the port of entry for the virus into cells leading to its replication in the host and to the consecutive spreading in the population. 3, 4 The ability of RBD-specific antibodies to prevent RBD binding to ACE2 can be measured with surrogate molecular interaction assays, 5 which mimic classical virus-neutralization tests 3 and can therefore be quickly adapted to newly emerging SARS-CoV-2 variants of concern by using RBDs from the corresponding virus variants.

Here, we compared the IgG recognition of RBD from the original | 1617 LETTERS and a random sample of adult subjects vaccinated two times (Table   S3 : D1-D10) or three times (Table S3: T1-T10) with a registered vec- tor-(i.e., Vaxzevria) and/or mRNA-based vaccine (i.e., Comirnaty) (Figures 1 and 2; Table S4 ). Furthermore, we studied the ability of antibodies in these sera to inhibit the binding of RBD-Wuhan, RBD-Delta, and RBD-Omicron to ACE2 using the RBD-ACE2 molecular interaction assay described by Gattinger et al. 5 (Figures 1 and 2 , Table S4 ). Sera from convalescent patients had been obtained from April to July 2020, 3 43-92 days (median 57.5 days) after the PCR confirmation of SARS-CoV-2 infection, sera from subjects vaccinated two times had been collected 26-31 days (median 27.5 days), and samples from subjects vaccinated three times were collected 23-40 days (median 28 days) after the last vaccination, respectively (Tables S2 and S3 ). There were no significant differences, regarding the levels of IgG antibodies specific for RBD-Wuhan (Table S4: Median OD C1-C20: 0.385; Median OD D1-D10: 0.453; Median OD T1-T10: 2.339) and RBD-Delta (Table S4 : Median OD C1-C20: 0.379; Median OD D1-D10: 0.509; Median OD T1-T10: 2.470) ( Table   S4 , Median reduction in binding comparing RBD-Wuhan with RBD-Delta: 4.3%), whereas RBD-Omicron-specific IgG levels (Table S4: Median OD C1-C20: 0.073; Median OD D1-D10: 0.128; Median OD T1-T10: 0.836) were significantly lower than those specific for RBD-Wuhan (Table S4, Table S4 ).

The RBD-specific IgG levels were in agreement with the results obtained regarding the inhibition of the RBD-ACE2 interaction by serum antibodies (Figure 1D -F). Antibodies from convalescent patients inhibited the binding of RBD-Wuhan and of RBD-Delta to ACE2 significantly stronger than the binding of RBD-Omicron to ACE2 ( Figure 1D ). In fact, RBD-Omicron binding to ACE2 was not inhibited by sera from convalescent patients in a relevant manner ( Figure 1D ). The inhibition of RBD-Omicron binding to ACE2 by sera from subjects who had received two immunizations was much lower than that observed for RBD-Wuhan (Table S4 , Median reduction in inhibition 87.8%) and RBD-Delta but did not reach significance because a considerable number of these subjects vaccinated with Vaxzevria mounted significantly lower levels of S-and RBD-specific antibodies than those vaccinated twice with Comirnaty ( Figure 2 ).

F I G U R E 1 RBD-specificIgGresponses to variants of concern in convalescent patients and vaccinated subjects. 

doses of Vaxzevria as compared with two doses of Comirnaty was also noted in another recent study. 6 In subjects vaccinated three times, the inhibition of RBD-Omicron binding to ACE2 was significantly lower than that of RBD-Wuhan binding to ACE2 (Table S4, Median reduction of inhibition 27.7%) with two out of ten subjects (i.e., T1, T3, and Table S4 ) showing less than 50% inhibition. Figure 2 shows that the IgG antibody levels specific for S, RBD-Wuhan, RBD-Delta, and RBD-Omicron were higher in subjects who had received three immunizations than in those who had received two immunization, and this difference was significant for two doses of Vaxzevria. In fact, the inhibition of the binding of RBD-Wuhan, RBD-Delta, and RBD-Omicron to ACE2 was higher in subjects immunized with two doses of Comirnaty than in those who had received two doses of Vaxzevria ( Figure 2E -G).

Median RBD-Omicron-specific IgG levels were lower in subjects having received 2 doses of Vaxzevria and a third dose of Comirnaty, than in those who had been immunized with three doses of Comirnaty but this difference was not significant ( Figure 2D ).

Interestingly, the median inhibition of RBD-Omicron binding to ACE2 was better for subjects treated 2xVaxzevria/1xComirnaty than for subjects treated with three doses Comirnaty ( Figure 2G ) but this difference was also not statistically significant.

To study if the degree of inhibition in the RBD-ACE2 interaction of the variants is depending only on the levels of RBD-specific antibodies or if also other factors such as specificity and/or avidity of antibodies 7 may play a role, we analyzed RBD levels and percentages of inhibition in parallel (Table S4 ). We found, that certain subjects (e.g., T1 and T3, Table S4 ) had relatively low levels of RBD-Omicron-specific IgG, and accordingly, there was no (i.e., T1) or low (i.e., T3) inhibition of RBD-Omicron binding to ACE2. However, we also found subjects with low levels of RBD-Omicron-specific IgG (i.e., T7, T8, and T10) with high inhibition of RBD-Omicron binding to ACE 2 (Table S4 ). This result together with the finding that the RBD-Omicron binding to ACE2 was even enhanced >20% for several convalescent patients ( Figure 1D ; Table S4: C1, C2, C4, C5, C9, C11, C16, C17, C19, and C20) would suggest, that factors, such as specificity and thus ability to form immune complexes 7 as well as affinities/avidities of antibodies and not only their levels may guide the RBD-Omicron-ACE2 interaction. 5, 7 In fact, we 5 4 However, during the same period in the UK, after an initial abrupt reduction, nitrogen dioxide (NO 2 ) increased gradually, suggesting that the early return of vehicles to the road during the lockdown had already offset much of the temporary air-quality improvement. 5 Regarding health impact, the risk of COVID-19 mortality during lockdown diminished alongside major air pollutants in Delhi, India, 6 but not in Mexico City, Mexico, where an inverse relationship was found in the case of fine particulate matter. 7 Furthermore, no reduction in COVID-19 deaths was associated with lockdowns as defined by social isolation (staying at home) in 87 regions and countries in the world. 8 We used the Spring 2020 lockdown as a natural experiment to understand what happened to the COVID-19 syndemic in terms of mortality when air pollution due to the lockdown restriction in terms of circulation and mobility was abruptly lowered in the European region, providing a distinct look at short-term health impacts of lockdown to compare against the long-term health impacts observed in previous studies relating air pollution exposure to COVID-19 events in highly polluted zones. 1 COVID-19 provides a choice criterion for such a comparison because it is a specific disease, which was the same in each country at the start of the epidemics.

To this extent, we compared the impact of lockdown restrictions, namely isolation instituted as a security measure, taken for people on air quality during the first lockdown and the first phase of unlocking with respect to COVID-19 mortality in 33 countries of the European region. The analysis timespan for each country ranged from the date of the first day of lockdown until 20 July 2020 (the cutoff date for the analysis). Daily COVID-19 mortality data

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa

Neutralization of SARS-CoV-2 requires antibodies against conformational receptorbinding domain epitopes

Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks

Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding

SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent Persons

Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses